Homology Medicines Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.16
- Today's High:
- $1.19
- Open Price:
- $1.16
- 52W Low:
- $0.86
- 52W High:
- $3.3
- Prev. Close:
- $1.17
- Volume:
- 38939
Company Statistics
- Market Cap.:
- $57.22 million
- Book Value:
- 2.628
- Revenue TTM:
- $3.21 million
- Operating Margin TTM:
- -3839.59%
- Gross Profit TTM:
- $-95143000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.26%
- Return on Equity TTM:
- -60.24%
Company Profile
Homology Medicines Inc had its IPO on 2018-03-28 under the ticker symbol FIXX.
The company operates in the Healthcare sector and Biotechnology industry. Homology Medicines Inc has a staff strength of 92 employees.
Stock update
Shares of Homology Medicines Inc opened at $1.16 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.16 - $1.19, and closed at $1.17.
This is a 0% increase from the previous day's closing price.
A total volume of 38,939 shares were traded at the close of the day’s session.
In the last one week, shares of Homology Medicines Inc have slipped by -2.5%.
Homology Medicines Inc's Key Ratios
Homology Medicines Inc has a market cap of $57.22 million, indicating a price to book ratio of 0.4289 and a price to sales ratio of 26.8768.
In the last 12-months Homology Medicines Inc’s revenue was $3.21 million with a gross profit of $-95143000 and an EBITDA of $-122004000. The EBITDA ratio measures Homology Medicines Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Homology Medicines Inc’s operating margin was -3839.59% while its return on assets stood at -30.26% with a return of equity of -60.24%.
In Q1, Homology Medicines Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Homology Medicines Inc’s PE and PEG Ratio
- Forward PE
- 22.2717
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.23 per share while it has a forward price to earnings multiple of 22.2717 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Homology Medicines Inc’s profitability.
Homology Medicines Inc stock is trading at a EV to sales ratio of 0.4068 and a EV to EBITDA ratio of 0.6307. Its price to sales ratio in the trailing 12-months stood at 26.8768.
Homology Medicines Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $197.88 million
- Total Liabilities
- $18.51 million
- Operating Cash Flow
- $31.37 million
- Capital Expenditure
- $228000
- Dividend Payout Ratio
- 0%
Homology Medicines Inc ended 2024 with $197.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $197.88 million while shareholder equity stood at $151.90 million.
Homology Medicines Inc ended 2024 with $0 in deferred long-term liabilities, $18.51 million in other current liabilities, 6000.00 in common stock, $-457981000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $39.45 million and cash and short-term investments were $150.03 million. The company’s total short-term debt was $1,626,000 while long-term debt stood at $0.
Homology Medicines Inc’s total current assets stands at $153.58 million while long-term investments were $23.04 million and short-term investments were $110.57 million. Its net receivables were $0 compared to accounts payable of $3.64 million and inventory worth $0.
In 2024, Homology Medicines Inc's operating cash flow was $31.37 million while its capital expenditure stood at $228000.
Comparatively, Homology Medicines Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.17
- 52-Week High
- $3.3
- 52-Week Low
- $0.86
- Analyst Target Price
- $7
Homology Medicines Inc stock is currently trading at $1.17 per share. It touched a 52-week high of $3.3 and a 52-week low of $3.3. Analysts tracking the stock have a 12-month average target price of $7.
Its 50-day moving average was $1.12 and 200-day moving average was $1.2 The short ratio stood at 2.95 indicating a short percent outstanding of 0%.
Around 918.5% of the company’s stock are held by insiders while 4746.3% are held by institutions.
Frequently Asked Questions About Homology Medicines Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company’s various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.